A phase 1/2 study of VS-6766 (RAF/MEK clamp) in combination with sotorasib (G12C inhibitor) in patients with KRAS G12C mutant non-small cell lung cancer (NSCLC) (RAMP 203).

被引：0
|
作者：
Govindan, Ramaswamy
Awad, Mark M.
Gadgeel, Shirish M.
Pachter, Jonathan A.
Patrick, Gloria
Denis, Louis J.
机构：
[1] Washington Univ, Sch Med, St Louis, MO USA
[2] Dana Farber Canc Inst, Boston, MA USA
[3] Henry Ford Canc Inst, Detroit, MI USA
[4] Verastem Inc, Needham, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS9148
引用
收藏
页数：1
相关论文
共 50 条
  • [31] A Phase 1B Trial of Tarloxotinib and Sotorasib in Lung Cancer Patients with KRAS G12C Mutations
    Alexander, M.
    Tirunagaru, V. G.
    Doebele, R. C.
    Wrangle, J. M.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S361 - S361
  • [32] Mixed response to the first-line treatment of KRAS G12C inhibitor, sotorasib, in non-small cell lung cancer: A brief report
    Yang, Jiao
    Huang, Jie
    Yuan, Gongjun
    Lin, Xiao-Cheng
    Chen, Hua-Jun
    Yang, Jin-Ji
    CLINICAL CASE REPORTS, 2024, 12 (06):
  • [33] Sotorasib versus docetaxel for previously treated non-small cell lung cancer with KRAS G12C mutation: CodeBreaK 200 phase III study
    Johnson, M. L.
    de langen, A. J.
    Waterhouse, D. M.
    Mazieres, J.
    Dingemans, A-M. C.
    Mountzios, G.
    Pless, M.
    Wolf, J.
    Schuler, M.
    Lena, H.
    Skoulidis, F.
    Okamoto, I.
    Kim, S-W.
    Linardou, H.
    Novello, S.
    Chen, Y.
    Solomon, B.
    Obiozor, C.
    Wang, Y.
    Paz-Ares, L.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1417 - S1418
  • [34] CodeBreak 200: A phase III multicenter study of sotorasib (AMG 510), a KRAS(G12C) inhibitor, versus docetaxel in patients with previously treated advanced non-small cell lung cancer (NSCLC) harboring KRAS p.G12C mutation
    Reck, M.
    Spira, A.
    Besse, B.
    Wolf, J.
    Skoulidis, F.
    Borghaei, H.
    Goto, K.
    Park, K.
    Griesinger, F.
    Felip, E.
    Boyer, M.
    Barrios, C. H.
    Goss, G.
    Yang, H.
    Obiozor, C.
    Ramalingam, S. S.
    ANNALS OF ONCOLOGY, 2020, 31 : S894 - S895
  • [35] Epithelial-to-Mesenchymal Transition is a Cause of Both Intrinsic and Acquired Resistance to KRAS G12C Inhibitor in KRAS G12C-Mutant Non-Small Cell Lung Cancer
    Adachi, Yuta
    Ito, Kentaro
    Hayashi, Yuko
    Kimura, Ryo
    Tan, Tuan Zea
    Yamaguchi, Rui
    Ebi, Hiromichi
    CLINICAL CANCER RESEARCH, 2020, 26 (22) : 5962 - 5973
  • [36] Phase I A Study to Evaluate GDC-6036 Monotherapy in Patients with Non-small Cell Lung Cancer (NSCLC) with KRAS G12C Mutation
    Sacher, A.
    Patel, M. R.
    Miller, W. H., Jr.
    Desai, J.
    Garralda, E.
    Bowyer, S.
    Kim, T. W.
    De Miguel, M.
    Falcon, A.
    Krebs, M. G.
    Lee, J.
    Cheng, M.
    Han, S. -W.
    Shacham-Shmueli, E.
    Forster, M.
    Jerusalem, G.
    Massarelli, E.
    Paz-Ares Rodriguez, L.
    Prenen, H.
    Walpole, I.
    Arbour, K.
    Choi, Y.
    Dharia, N. V.
    Lin, M.
    Mandlekar, S.
    Joo, S. Royer
    Shi, Z.
    Schutzman, J.
    LoRusso, P.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S8 - S9
  • [37] Sotorasib vs Adagrasib: Matching-adjusted Indirect Comparison in Prior Treated KRAS G12C Advanced Non-Small Cell Lung Cancer
    Chopra, D.
    Waterhouse, D. M.
    Sylvester, B.
    Jamotte, A.
    Stollenwerk, B.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S647 - S648
  • [38] Lumykras® (Sotorasib) receives EU Approval for Female Patients with KRAS G12C Mutation-positive Non-small Cell Lung Cancer
    Freye, Reimund
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (1-2) : 73 - 73
  • [39] Preclinical and clinical evaluation of the RAF/MEK clamp avutometinib (VS-6766) in combination with the mTOR inhibitor everolimus for the treatment of KRAS mutated non-small cell lung cancer
    Rodney, Simon
    Stewart, Adam R.
    Perez, Victoria Sanchez
    Morton, Cienne
    Pickard, Lisa A.
    Shakouri, Taleen
    Prout, Toby
    Parmar, Mona
    Turner, Alison J.
    Coma, Silvia
    Pachter, Jonathan
    Finneran, Laura
    Hall, Emma
    Spicer, James
    Minchom, Anna
    Banerji, Udai
    CANCER RESEARCH, 2023, 83 (07)
  • [40] A Phase 2 Trial of MRTX849 in Combination with Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation
    Spira, A.
    Riely, G.
    Lawler, W.
    Shum, M.
    Socinski, M.
    Yanagihara, R.
    Roshan, S.
    Kheoh, T.
    Christensen, J.
    Chao, R.
    Janne, P.
    Garassino, M.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S695 - S696
12345